InvestLog
Back to Market返回行情

CYBN Cybin Inc.

AMEXHealthcare
$8.28+1.22%OpenMarket Cap: $413.0M

As of 2026-01-02 16:00

Why CYBN matters now

Cybin Inc. (CYBN) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.28 with +1.22% on the session and $413.0M in market capitalization.

The latest indexable market news headline is "Cybin: A Speculative Bet On Their Pivotal Depression Readout" from Seeking Alpha.

Latest News

Cybin: A Speculative Bet On Their Pivotal Depression ReadoutSeeking Alpha · 2026-06-27
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and DirectorNewsfile Corp · 2026-05-13
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)Seeking Alpha · 2026-04-21
FTSE 100 Live: London stocks slide as aerospace and defence sector fallsProactive Investors - Finance · 2026-04-21
Psychedelics stocks rise after Trump order expands research, access pathwaysProactive Investors - Finance · 2026-04-20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

CA

Exchange

AMEX

Beta

0.79

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.